



FOR IMMEDIATE RELEASE

September 1, 2006

www.clinilabs.com

www.cognitivedrugresearch.com

CLINILABS AND COGNITIVE DRUG RESEARCH FORM STRATEGIC ALLIANCE

Two leaders in CNS clinical trials collaborate to provide premium services to sponsors

Clinilabs, Inc. and Cognitive Drug Research (CDR) have formed a non-exclusive strategic alliance, bringing together two leaders in CNS clinical trials to provide an optimal environment for cognition assessment. CDR's gold standard cognition assessment equipment will be permanently hosted at Clinilabs' premier phase I-IV research site in New York City. The creation of this 'super-site' offers clients a one-stop-shop for cognition assessment, bringing with it the advantages of ready trained site staff, expert consultation on cognition assessment and a full range of clinical trial site services.

Clinilabs operates a state-of-the-art, 24,400 sq. ft., 40-bed clinical trial site in midtown Manhattan. This site is regarded as a center of excellence for CNS and cardiology trials, with a special emphasis in sleep. Clinilabs' team of physicians, nurse practitioners, physician assistants, clinical research coordinators, laboratory technologists, subject recruiters, and support staff provide an unparalleled level of service to industry sponsors. The company is a technology-based clinical trials organization and provides drug development services to pharmaceutical and biotechnology companies. They offer electronic data capture, project management, and electronic patient recruitment services for multicenter trials worldwide using validated, 21 CFR Part 11 compliant systems.

Cognitive Drug Research is the world's leading provider of innovative cognitive function assessment technology. Headquartered in the UK, CDR has employed its laptop-based cognition assessment system in over 500 phase I-IV clinical trials around the world and is validated in over 45 languages. CDR has recently established an office in the United States. Located in Chicago, CDR's US office strengthens CDR's already significant presence in the US and offers greater convenience to US clients in terms of both logistics and business operations. This year CDR celebrated 20 years as the market leaders in the automated assessment of human cognitive function.

CDR's solution combines the most accurate cognition testing technology available, with unrivaled expert analysis and interpretation of results supported by the largest known database of cognitive performance levels. The system is highly sensitive to alterations in cognitive function produced by pharmaceutical and nutraceutical compounds, ageing and disease.

In a joint statement released by the companies, Dr. Gary Zammit, President & CEO of Clinilabs, and Dr. Keith Wesnes, President and CEO of CDR, have announced that "this alliance allows sponsors to design and execute CNS research studies quickly and efficiently." Through this partnership, Clinilabs recognizes Cognitive Drug Research as its preferred choice for all clinical trials involving cognitive testing in early phases of drug development. In turn, Cognitive Drug Research are proud to recognize Clinilabs as a dedicated CDR super-site.

Contacts: Mennato Forgione (Clinilabs) 212-994-4141 / mforgione@clinilabs.com
Steve Satek (CDR) 773-293-4053 / steves@cognitivedrugresearch.com